Chef de produit junior oncologie (tumeurs solides) en stage Early Career (Fixed Term), Full time Marketing Frankreich Paris Headquarter (Novartis Pharma S.A.S.) Dez 16, 2025 ...

Patient Engagement Therapeutic Area Manager Regular, Full time Development United Kingdom +Alternative Locations London (The Westworks) dez 16, 2025 ...

Prozkoumejte pracovní příležitosti ve společnosti Novartis v seznamu níže. Expert Scientific Writer Regular, Full time Development Ireland Dublin (NOCC) pro 08, 2025 Associate Director, Global ...

Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix ® for patients living with cancer. Scemblix ® (asciminib) ...

Albania Alemania Angola Arabia Saudí Argelia Argentina Armenia Australia Austria Azerbaiyán Bahamas Bahráin Bangladesh Barbados Bélgica Benín Bermudas Bielorrusia Bolivia Bosnia-Herzegovina Brasil ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Εξερευνήστε ευκαιρίες στη Novartis παρακάτω. Analyst - Quality Operations Regulär, Full time Other India Hyderabad (Office) Δεκ 16, 2025 Territory Business Executive - Ahmedabad Regulär (Außendienst), ...

Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...

Sort by Sort ascending 職種Sort ascending 部門国勤務地掲載日 職種Sort ascending 部門国勤務地掲載日 Representante de Ventas Oncología CDMXRegulär (Außendienst), Full time Marketing Mexico INSURGENTES Dec 11, 2025 ...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...

Geplante Investitionen in die Schweizer Produktionsstandorte von über USD 100 Mio. – USD 80 Mio. am Standort Schweizerhalle in die Herstellung von siRNA und USD 26 Mio. in die Produktion steriler ...